Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.

ABSTRACT:

Background

Shared learnings from the early use of novel therapies can aid in their optimization. The recent introduction of peanut oral immunotherapy (peanut OIT; Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]) for peanut allergy addresses a significant unmet need but also highlights the requirement for consideration of several factors by both prescribers and patients.

Objective

To provide guidance for prescribers of licenced peanut OIT to facilitate treatment delivery and improve outcomes.

Methods

Clinicians with experience of licenced peanut OIT (United States n = 6, United Kingdom n = 1) participated in a series of interviews and group discussions designed to elicit tips for successful implementation.

Results

Clinicians identified 8 tips that wer

SUBMITTER: Portnoy J 

PROVIDER: S-EPMC9088027 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature